What Is New in Anti–Immunoglobulin E Asthma Therapy
Omalizumab, a recombinant humanized monoclonal antibody, is the first therapeutic agent specifically targeting immunoglobulin E (IgE). It has been investigated extensively in the treatment of patients with allergic diseases and is approved in the United States for the treatment of patients with moderate-to-severe persistent asthma. In this setting, omalizumab reduced the frequency and incidence of asthma exacerbations and asthma control was well maintained, even though patients significantly reduced their dose of inhaled corticosteroid. Importantly, omalizumab has been shown to reduce asthma exacerbations in high-risk patients (e.g., with previous intubation and hospitalization) and to reduce the level of severe asthma exacerbations (those resulting in emergency treatment and hospitalization). Responder analysis shows that omalizumab provides the greatest benefit in patients with more severe asthma, and this has been confirmed by recent studies establishing the efficacy of omalizumab in patients whose asthma is poorly controlled despite receiving the best standard care in medication. Omalizumab also has proved to be effective in patients with seasonal and perennial allergic rhinitis and to improve quality of life for patients with asthma or rhinitis. As expected with a systemic anti-IgE agent, omalizumab was shown to be effective in the treatment of patients with concomitant asthma and allergic rhinitis. The efficacy of omalizumab in a range of allergic diseases reaffirms the importance of IgE in the pathogenesis of these conditions and establishes the potential benefit to be obtained by inhibiting IgE, especially in patients with more severe and comorbid allergic diseases.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Publication date: 01 November 2005
More about this publication?
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
- Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Ingenta Connect is not responsible for the content or availability of external websites